---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030118"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:04:08.276510+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences settles SEC probe for $40M; DOJ not expected to charge company

## Summary
- Agreed to pay $40M civil penalty without admitting or denying SEC allegations of negligence-based disclosure violations.
- Resolution covers statements about 2020 Phase 2b simufilam trial; DOJ Criminal Division not expected to bring charges.
- Rick Barry appointed Executive Chairman (July 17) and CEO (Sept 6) as part of governance enhancements.
- Net cash use H2 2024 estimated $80-90M including penalty; year-end cash projected $117-127M.
- Settlement subject to U.S. District Court approval; company had previously reserved $40M loss contingency.

## SEC filing metadata
- accession: 0001437749-24-030118
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030118/0001437749-24-030118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030118/sava20240927_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030118
- JSON: https://secwatch.observer/filing/0001437749-24-030118.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.